F . ENT COOPERATION TREAS

РСТ	From the INTERNATIONAL BUREAU
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis.1 and Administrative Instructions, Section 422) Date of mailing (day/month/year) 14 February 2002 (14.02.02)	WALKER, Ralph, Francis GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford Middlesex TW8 9GS ROYAUME-UNI
Applicant's or agent's file reference RFW/P32374 International application No.	IMPORTANT NOTIFICATION
PCT/EP00/07295	International filing date (day/month/year) 27 July 2000 (27.07.00)
The following indications appeared on record concerning: the applicant the inventor the inventor	X the agent the common representative
Name and Address WALKER, Ralph, Francis SmithKline Beecham Corporate Intellectual Property Two New Horizons Court Brentford Middlesex TW8 9EP United Kingdom	Telephone No. 44 127 967 6336 Facsimile No. 44 181 975 6294 Teleprinter No.
The International Bureau hereby notifies the applicant that the person	
Name and Address WALKER, Ralph, Francis GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom	State of Nationality Telephone No. +44 208 047 5000 Facsimile No. +44 208 047 6894 Teleprinter No.
3. Further observations, if necessary:	
4. A copy of this notification has been sent to: X the receiving Office the International Searching Authority the International Preliminary Examining Authority	the designated Offices concerned X the elected Offices concerned other:
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Sean Taylor
acsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338 83 38

P ENT COOPERATION TREAT

DOT	From the INTERNATIONAL BUREAU
PCT NOTIFICATION OF ELECTION (PCT Rule 61.2)	Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202
Date of mailing (day/month/year) 03 April 2001 (03.04.01)	ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/EP00/07295	Applicant's or agent's file reference RFW/P32374
International filing date (day/month/year) 27 July 2000 (27.07.00) Applicant	Priority date (day/month/year) 30 July 1999 (30.07.99)
CLARKE, Allan, J. et al	
1. The designated Office is hereby notified of its election made X in the demand filed with the International Preliminary 03 February 200 in a notice effecting later election filed with the Interna 2. The election X was was not was not was not made before the expiration of 19 months from the priority date Rule 32.2(b).	Examining Authority on: D1 (03.02.01) tional Bureau on:

Authorized officer

Telephone No.: (41-22) 338.83.38

Pascal Piriou

Form PCT/IB/331 (July 1992)

Facsimile No.: (41-22) 740.14.35

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

PCT

REC'D 2 9 OCT 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORTS

(PCT Article 36 and Rule 70)

Applicar	t's or agent's file reference		
ļ	W/P32374	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
	onal application No. P00/07295	International filing date (day/mont 27/07/2000	h/year) Priority date (day/month/year) 30/07/1999
Applicant SMITHI 1. This and	KLINE BEECHAM PLC et international preliminary exaits transmitted to the applicar	al.	by this International Preliminary Examining Authority
Thes	see Rule 70.16 and Section e annexes consist of a total o	607 of the Administrative Instruction	e description, claims and/or drawings which have ontaining rectifications made before this Authority ns under the PCT).
	eport contains indications rel	ating to the following items:	
- 1	☐ Basis of the report		
111	☐ Priority ☐ Non-establishment of		
IV	Lack of unity of inventi	pinion with regard to novelty, inve	ntive step and industrial applicability
. v	and or army or miverill	OH	
•	citations and explanati	nder Article 35(2) with regard to no ons suporting such statement	velty, inventive step or industrial applicability;
VI	☐ Certain documents cit		
VII	Certain defects in the in	nternational application	
VIII	☑ Certain observations of	n the international application	
Date of subm	ission of the demand	Date of con	npletion of this report
03/02/200		25.10.2001	
Name and ma preliminary ex	ailing address of the international camining authority:	Authorized	officer
	European Patent Office		STANSONES MICHIGAN
<i></i>	0-80298 Munich Fel. +49 89 2399 - 0 Tx: 523656 Fax: +49 89 2399 - 4465	epmu d Muller, I	The search
orm PCT/IPEA/409 (cover sheet) (Jacuary 1994)			lo. +49 89 2399 8716





. Basis	of t	he i	report	
---------	------	------	--------	--

	1.	With regard to the el the receiving Office is and are not annexed Description, pages	lements of the international application (Replacement sheets which have been furnished to in response to an invitation under Article 14 are referred to in this report as "originally filed" to this report since they do not contain amendments (Rules 70.16 and 70.17)):
		1-30	as originally filed
	(Claims, No.:	
	1	I-37	as originally filed
	[Prawings, sheets:	
	1	/7-7/7	as originally filed
2.	W la	ith regard to the lang nguage in which the	guage, all the elements marked above were available or furnished to this Authority in the international application was filed, unless otherwise indicated under this item.
	Th	nese elements were a	available or furnished to this Authority in the following language: , which is:
		the language of a	translation furnished for the purposes of the international search (under Rule 23.1(b)).
		anguage of pu	isheation of the international application (under Rule 49.2(b))
		the language of a t 55.2 and/or 55.3).	ranslation furnished for the purposes of international preliminary examination (under Rule
3. 'i	Wit	th regard to any nucl ernational preliminary	leotide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:
[contained in the inte	ernational application in written form.
		filed together with the	ne international application in computer readable form.
[furnished subseque	ently to this Authority in written form.
		furnished subseque	ntly to this Authority in computer readable form
]	the international app	the subsequently furnished written sequence listing does not go beyond the disclosure in Dication as filed has been furnished.
L		The statement that t listing has been furn	he information recorded in computer readable form is identical to the written sequence ished.
4. TI	he	amendments have re	esulted in the cancellation of:
]	the description,	pages:
	1	the claims,	Nos.:





	the drawings,	sheets:		
5. 🗆	This report has been considered to go bey (Any replacement shoreport.)	establis ond the eet conta	hed as if disclosure	(some of) the amendments had not been made, since they have been e as filed (Rule 70.2(c)): The amendments must be referred to under item 1 and annexed to this
6. Add	litional observations, if	necessa	ary:	
V. Reascitat	soned statement und ions and explanation ement	er Artic s suppo	le 35(2) w orting sud	vith regard to novelty, inventive step or industrial applicability; ch statement
Nove	elty (N)	Yes: No:	Claims Claims	
Inven	itive step (IS)	Yes: No:	Claims Claims	
Indus	trial applicability (IA)	Yes: No:	Claims Claims	1-37
2. Citatio	ons and explanations			

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

see separate sheet



International application No. PCT/EP00/07295 **EXAMINATION REPORT - SEPARATE SHEET**

Re Item I

Basis of the report

The amendments filed with telefax dated 24.09.2001 cannot be taken into consideration in the present opinion, for following reasons:

No clear basis in the application as originally filed can be found, respectively has been indicated for the subject-matter of following amended claims:

- The technical features of claim 1 are extracted from multiple claims (claims 28 and i) 16-18, several of which refer to a multitude of other claims.
- Claim 5 is not based on the original claims, no clear basis is further apparent from ii) the specification. Reference to cylindrical shape in the description at p. 4, for instance, relates to sub-units in general or solid sub-units. iii)
- The same as stated under item i) applies to the dependent claims 2-4 and 6-17.
- The subject-matter of independent claim 18 introduces subject-matter going iv) beyond the application as originally filed. Original claim 5, referring to claim 1 for instance includes precise definition of the general term sub-unit, i.e. sub-units each selected from capsule compartments ../.. and solid sub-units ../... In contrast, new claim 18 merely defines at least one solid sub-unit, the remaining sub-units of the multi-component dosage form not being specified.
- The same rationale as noted under iv) applies to new independent claim 22, with V) the difference that sole definition is made of the capsule compartments. Hence, the requirement set forth by Article 34(2)(b) PCT has not been met.

Consequently, the present international preliminary examination report is drawn up on the basis of claims 1-37 as originally filed.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: US-A-5 074 426 (GOODHART FRANK W ET AL) 24 December 1991 (1991-

D2: US-A-4 738 817 (WITTWER FRITZ ET AL) 19 April 1988 (1988-04-19) cited in the application



EXAMINATION REPORT - SEPARATE SHEET

D3: US-A-5 674 530 (CRISON JOHN R ET AL) 7 October 1997 (1997-10-07). D4: WO 95 16438 A (CORTECS LTD ;BARNWELL STEPHEN GEORGE (GB); HIGGINBOTTOM SIMON (GB)) 22 June 1995 (1995-06-22) cited in the application.

- 2. Novelty (Article 33(2) PCT) Claim 1 is understood as defining a dosage form containing sub-units. Each of said sub-units being selected from i) capsule compartments, ii) solid sub-units. Each of said sub-units containing a drug substance (for the capsule compartments in view of defining the latter as that they can release their drug substance).
- The subject-matter of the independent claim 1 is anticipated by D1 and D2: 2.1
- D1 discloses pharmaceutical capsules, dividable into individual dosage units, comprising first and second capsule units, each holding a medicinal preparation (see col. 1, I. 33-37, different sort of drugs). These capsule units representing subunits which are connected to form an assembled dosage form. The connection being provided by an adhesive weld and/or an annular band and/or locking mechanical means (see claims 2-11). Further, the connection may be formed by a hollow cylindrical member open at one end of one capsule unit and the respectively fitting cap at one end of the other capsule unit (see claims 12-15 of D1 in view of plug and socket connectable parts).

It is further noted that for example the capsules of D1 can comprise more than two capsule compartments (see for instance figures 17 and 18), at least two of which are interchangeable, being separated by a wall; referring to figures 13 and 14, the adjacent capsule wall material may be made of hard gelatine (see col. 5, l. 13-16).

- D2 discloses pharmaceutical capsules of gelatine, comprising a plurality of capsule compartments, filled with the same or complementary drug, connected for example by means of ratchet teeth (see also figure 38; col. 12, I. 58 - col. 13, I. 5).
- 2.2 None of the documents cited in the international search report defines a process for manufacturing a dosage form as defined in present independent claim 37, comprising a linker having at two opposite sides plug parts which are inserted into



the open ends of the, with drug filled, capsule compartments. Hence, the subject-matter of claim 37 is considered satisfying the requirement of Art. 33(2) PCT.

Inventive Step (Article 33(3) PCT) 3.

The difference between the subject-matter of process claim 37 and the documents D1-D4 consists of the insertion of a linker having at two opposite sides plug parts into the open ends of the two capsule compartments in order to provide both assembly and closure of the two capsule compartment units. The 'welding of the linker in place' is not considered as delimiting feature, as this step may comprise for example simply fitting of the respective sub-units in place.

The problem underlying present claim 37 is considered as providing an alternative process for the manufacture of multiple compartment dosage forms.

The use of a linker for closing and fixing two separate capsule compartments is known from D1 (see for example figure 9, however, not having the form of plug connectable parts; figures 13/14 disclosing a two piece linking element 60/64, however manufactured by filling the units 60/64 with the desired medicinal preparation, then seal with caps 62 and 66, cf. col. 4, I. 67 - col. 5, I. 4). D2 (disclosing the application of a disc-like cover plate, see for example figure 38) and D4 (using barrier material to be filled onto the first fill composition before further filling of a second fill composition, see p. 8, I. 28-32) lack the linking element for insertion into the capsule sub-units. The same as for D2 and D4 applies to D3 (one end plugging of an open first capsule half after filling with drug and an osmotic agent, the plug not functioning as two plug-part-linker, see figure-2). In view that the order of proceeding in the manufacture of a delivery system disclosed in D3 is similar to present claim 37 (see col. 2, I. 46-55), this document is considered as closest prior art.

Considering the teaching of D1-D4, no hint is apparent that would lead the skilled person to manufacture a dosage form by using a linker with, at opposite side, plug parts in order to provide a dosage form of assembled capsule compartments. Hence, claim 37 is considered satisfying the requirements of Art. 33(3) PCT.



- Industrial Applicability (Article 33(4) PCT) 4. The subject-matter of the claims 1-37 is applicable in the pharmaceutic industry.
- A positive preliminary examination report for the dependent claims can only be 5. established when the requirements of the PCT for the independent claims are complied with.

Re Item VIII

Certain observations on the international application

- Claim 1 defines the sub-units of the dosage form (capsule compartments and 1. solid sub-units) as comprising drug substance (in view of reference to capsule compartments as their drug substance), whereas in the dependent claims 3 and 6, referring to claim 1, solely part of the contained capsule compartments may contain drug substance (see one or more of the capsule compartments), and thus, leading to a lack of clarity of the subject-matter of claim 1 (Art. 6 PCT).
- 2. The meaning of the feature of 'the sub-units being retained together by the connection at least prior to administration is unclear and hence, has not been taken into consideration for above assessment of novelty and inventive step.

From the INTERNATIONAL SEARCHING AUTHORITY To: SmithKline Beecham NOTIFICATION OF TRANSMITTAL OF Corporate Intellectual Property THE INTERNATIONAL SEARCH REPORT 2000 Attn. WALGER, Ralph Francis OR THE DECLARATION Two New Horizons Court Brentford (PCT Rule 44.1) Middlesex TW8 9EP UNITED KINGDOM Date of mailing (day/month/year) 15/12/2000 Applicant's or agent's file reference RFW/P32374 FOR FURTHER ACTION See paragraphs 1 and 4 below International application No. International filing date PCT/EP 00/07295 (day/month/year) 27/07/2000 Applicant SMITHKLINE BEECHAM PLC 1. X The applicant is hereby notified that the International Search Report has been established and is transmitted herewith. Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46): When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet. Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41-22) 740.14.35 For more detailed instructions, see the notes on the accompanying sheet. The applicant is hereby notified that no International Search Report will be established and that the declaration under With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that: the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made. 4. Further action(s): The applicant is reminded of the following: Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90*bis*.1 and 90*bis*.3, respectively, before the completion of the technical preparations for international publication. Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later). Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II. Name and mailing address of the International Searching Authority

Authorized officer

Catherine Humbert

. Fax: (+31-70) 340-3016

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

NO TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international politication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French.

The letter must indicate the differences between the claims as filed and the claims as amended, it must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]:
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
- *Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged.*

 4. [Where various kinds of amendments are made]:

 Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added.

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published. $^\circ$

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference RFW/P32374	FOR FURTHER see Notification of (Form PCT/ISA/2	of Transmittal of International Search Report (20) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	
PCT/EP 00/07295		(Earliest) Priority Date (day/month/year)
Applicant Applicant	27/07/2000	30/07/1999
SMITHKLINE BEECHAM PLC		
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searching Auth ansmitted to the International Bureau.	ority and is transmitted to the applicant
This International Search Report consists X It is also accompanied by	of a total of sheets. a copy of each prior art document cited in this	report.
1. Basis of the report		
With regard to the language, the language in which it was filed, unloading to the language in which it was filed.	nternational search was carried out on the basi ess otherwise indicated under this item.	is of the international application in the
* * * * * * * * * * * * * * * * * * * *	as carried out on the basis of a translation of th	
 With regard to any nucleotide and was carried out on the basis of the 	d/or amino acid sequence disclosed in the inte	ernational application, the international search
	nal application in written form.	
filed together with the inter	national application in computer readable form.	
furnished subsequently to	this Authority in written form.	
furnished subsequently to	this Authority in computer readble form.	
the statement that the infor furnished	mation recorded in computer readable form is i	dentical to the written sequence listing has been
	d unsearchable (See Box I).	
3. Unity of invention is lack	ng (see Box II).	
4. With regard to the title,		
the text is approved as sub	mitted by the applicant.	
X the text has been established	ed by this Authority to read as follows:	
MULTI-COMPONENT PHARMAG	CEUTICAL DOSAGE FORM	
5. With regard to the abstract,		
,		
the text is approved as subr	nitted by the applicant	
the text has been established	ed according to Bullo 20 0/h) his wife A was to	as it appears in Box III. The applicant may, t, submit comments to this Authority
the text has been established within one month from the disconnection.	ed, according to Rule 38.2(b), by this Authority a ate of mailing of this international search repor	as it appears in Box III. The applicant may, t, submit comments to this Authority.
the text has been established	ed, according to Rule 38.2(b), by this Authority a ate of mailing of this international search repor ned with the abstract is Figure No.	t, submit comments to this Authority.
the text has been established within one month from the displayed. The figure of the drawings to be published.	ed, according to Rule 38.2(b), by this Authority a ate of mailing of this international search repor- ned with the abstract is Figure No. nt.	as it appears in Box III. The applicant may, t, submit comments to this Authority. None of the figures.



A. CLASSIFICATION OF SUBJECT MAILER IPC 7 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC $\frac{7}{100}$ A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DC	CUMENTS	CONSIDERED	то	BE RELEVANT
_				

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	US 5 074 426 A (GOODHART FRANK W ET AL) 24 December 1991 (1991-12-24)	1,7, 9-11,13,
	column 1, line 33 - line 44 column 2, line 38 - line 42 column 4, line 1 -column 5, line 16 claims 1-14	15–18
(US 4 738 817 A (WITTWER FRITZ ET AL) 19 April 1988 (1988-04-19) cited in the application figure 38	1
	column 3, line 54 -column 4, line 68 column 12, line 59 -column 13, line 4 column 16, line 32 - line 47	

[V] Sustained	
Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
° Special categories of cited documents :	
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filling date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document reterring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filling date but later than the priority date claimed	 *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
Date of the actual completion of the international search	*&* document member of the same patent family Date of mailing of the international search report
8 December 2000	15/12/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Muller, S

Form PCT/ISA/210 (second sheet) (July 1992)

internationa	Application No	
/EP	00/07295	

C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	7 21 00/0/293
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 674 530 A (CRISON JOHN R ET AL) 7 October 1997 (1997-10-07) column 2, line 47 - line 55	37
A	WO 95 16438 A (CORTECS LTD ;BARNWELL STEPHEN GEORGE (GB); HIGGINBOTTOM SIMON (GB)) 22 June 1995 (1995-06-22) cited in the application page 8, line 28 -page 11, line 12	1-37
	!	
	ontinuation of second sheet) (July 1992)	

INTERNATIONAL SEARCH REPORT International Application No Intermation on patent family members /EP 00/07295 Patent document cited in search report Publication Patent family Publication

cited in search report	t 	date	member(s)		Publication date	
US 5074426	Α	24-12-1991	AT AU AU BR DE EP GR JP	65907 T 603614 B 8050587 A 8706068 A 3772023 A 0274345 A 3002447 T 63135174 A	15-08-1991 22-11-1990 19-05-1988 21-06-1988 12-09-1991 13-07-1988 30-12-1992 07-06-1988	
US 4738817	Α	19-04-1988	US US CH DE FR GB IT DE FR GB JP JP	4498080 A 4655840 A 664938 A 3438235 A 2555972 A 2148235 A,B 1178161 B 5061942 B 4738724 A 900950 A 661878 A 3438656 A 2554418 A 2148841 A,B 1178193 B 1947556 C 6073539 B 60132562 A	05-02-1985 07-04-1987 15-04-1988 30-05-1985 07-06-1985 30-05-1985 09-09-1987 07-09-1993 19-04-1988 30-04-1985 31-08-1987 23-05-1985 10-05-1985 05-06-1985 09-09-1987 10-07-1995 21-09-1994 15-07-1985	
	A 	07-10-1997 	US US	5387421 A 5976571 A	07-02-1995 02-11-1999	
√O 9516438	A	22-06-1995	AU AU BR CA CN EP JP NZ SG ZA	702464 B 1196795 A 9408294 A 2179041 A 1137235 A 0734253 A 9506606 T 277074 A 64292 A 9409931 A	25-02-1999 03-07-1995 26-08-1997 22-06-1995 04-12-1996 02-10-1996 30-06-1997 26-01-1998 27-04-1999 13-06-1996	

A. CLA	SSIFICATION OF SUBJECT MATTER		PCI/EP 00/11922
IPC :	7 A61K9/48 A61K9/20		
Accordin	ig to International Passes Co.		
B. FIELL	g to International Patent Classification (IPC) or to both nationa DS SEARCHED	I classification and IPC	
Minimum	documentation searched (classification system followed by	assification	
IPC 7	7 A61K	assincation symbols)	
Documen	ntation searched other than minimum documentation to the ext	and that ough day	
	The CAN	en trai such documents are include	d in the fields searched
Electronic	data hare consulted to		
CDO T	data base consulted during the international search (name of	data base and, where practical, se-	arch terms used)
Eru-I	nternal, WPI Data, PAJ, BIOSIS		
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, o	The relevant passages	
 		- Pussages	Relevant to claim No.
Υ	GB 1 298 084 A (E.R.A.S.M.E.;	CLAUDE B)	
	49 November 19/2 (1972-11-29)		1-7
	Seite 3, Beispiel 4, Zeile 10	7-118	1
Υ	GR 1 355 324 A (MIDY CA CLAUD	-	ļ
•	GB 1 355 324 A (MIDY SA;CLAUD 5 June 1974 (1974-06-05)	ER)	1-7
	example 1		
A	EP 0 704 207 A (ROEHM GMBH)		1-7
ĺ	3 April 1996 (1996-04-03)		1-/
	cited in the application examples 7-9		
Α	EP 0 727 205 A (ROEHM GMBH)		, ,
	21 August 1996 (1996-08-21)		1-7
	column 3, line 10 -column 3, 1	ine 28	
,	column 9, line 56 -column 10,	line 21	1
- 1		,	
		•	
Furthe	er documents are listed in the continuation of box C.		
		X Patent family membe	ers are listed in annex.
Special cate	egories of cited documents :	*T* later document published	
A* document consider	t defining the general state of the art which is not red to be of particular relevance		ifter the international filing date conflict with the application but
E" earlier do	current but published on or after the international	invention	inciple of theory underlying the
L* document	which may throw doubte on priority, stains (a)	"X" document of particular rele- cannot be considered nov	
citation o	or other special reason (as specified)	"Y" document of particular release	when the document is taken alone
O" document other me	t referring to an oral disclosure, use, exhibition or	document is combined wit	hone an inventive step when the
o document	published prior to the international filing date but the priority date claimed	ments, such combination to in the art.	being obvious to a person skilled
		*&" document member of the sa	ame patent family
01 1116 401	ual completion of the international search	Date of mailing of the interest	national search report
28	February 2001	07/02/225	İ
	ling address of the ISA	07/03/2001	
and man	European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	Tel. (+31-70) 340-2040. Tx. 31 651 eno ni		
	Fax: (+31-70) 340-3016	Borst, M	

	lr.	tion on patent family men	nbers	PCT	Application no	
Patent docur cited in search		Publication date		Patent family member(s)	Publication date	
GB 129808	34 A	29-11-1972	BE CA CH DE FR IT JP NL SE SU	743526 A 946281 A 506288 A 1965584 A 1605150 A 1044195 B 48031887 B 6919520 A 362011 B 396859 A	28-05-1970 30-04-1974 30-04-1971 23-07-1970 16-03-1973 20-03-1980 02-10-1973 02-07-1970 26-11-1973 29-08-1973	
GB 135532	4 А	05-06-1974	FR FR BE CA CH DE IT NL	2135021 A 2100561 A 770162 A 944689 A 540046 A 2137213 A 1044956 B 7110361 A	15-12-1972 24-03-1972 01-12-1971 02-04-1974 15-08-1973 16-03-1972 21-04-1980 01-02-1972	
EP 0704207	7 А	03-04-1996	DE CZ HU JP SK US	9414065 U 9502235 A 75239 A 8073378 A 106295 A 5705189 A	03-11-1994 13-03-1996 28-05-1997 19-03-1996 08-01-1997 06-01-1998	
EP 0727205	A	21-08-1996	DE JP	29502547 U 8245422 A	30-03-1995 24-09-1996	

INTERNATIONALER RECHERCHENBERICHT

				0/11922
A. KLAS IPK 7	A61K9/48 A61K9/20			
Nach der	nternationalen Patentklassifikation (IPK) oder nach der nationale	Klassifikation und der IDK		
B. RECH	ERCHIERTE GEBIETE			
IPK 7	erter Mindestprüfstoff (Klassifikationssystem und Klassifikationss A61K	ymbole)		
Recherchie	erte aber nicht zum Mindestprüfstoff gehörende Veröffentlichunge	n. soweit diese unter die rech	erchierten Gebiel	e fallen
Während d	er internationalen Recherche konsultierte elektronische Datenbar	k (Name der Dalenbank und	evtl. verwendete	Suchbegriffe)
EPO-In	ternal, WPI Data, PAJ, BIOSIS			•
C. ALS WE	BEZEICH ANGESEHENE UNTERLAGEN			
	Bezeichnung der Veröftentlichung, soweit erforderlich unter An-	gabe der in Betracht kommend	den Teile	Betr. Anspruch Nr.
Υ	GB 1 298 084 A (E.R.A.S.M.E.;CL	AUDE R)		1-7
	29. November 1972 (1972-11-29) Seite 3, Beispiel 4, Zeile 107-			1-7
	7			
Y	GB 1 355 324 A (MIDY SA;CLAUDE 5. Juni 1974 (1974-06-05)	R)		1-7
	Beispiel 1			
A	EP 0 704 207 A (ROEHM GMBH)			
	3. April 1996 (1996-04-03)			1-7
	in der Anmeldung erwähnt Beispiele 7-9			
A	EP 0 727 205 A (ROEHM GMBH) 21. August 1996 (1996-08-21)			1-7
	Spalte 3. Zeile 10 -Spalte 3 76	ile 28		
	Spalte 9, Zeile 56 -Spalte 10, Z	eile 21		
	;			
	•			
Weiten entneh	e Veröffentlichungen sind der Fortsetzung von Feld C zu men	X Siehe Anhang Pate	entfamilie	
Besondere K A* Veröffentli	ategorien von angegebenen Veröffentlichungen : chung, die den allgemeinen Stand der Technik definien,	'T' Spätere Veröffentlichung	l, die nach dem ir	ternationalen Anmeldedatum
E' älteres Do	kument, das jedoch erst am oder nach dem internationales	Anmeldung nicht kollidie Erfindung zugrundeliege	of sondern our a	rorden ist und mit der um Verständnis des der der der ihr zugrundeliegenden
.* Veröftentlik	chung, die geeignet ist, einen Prostätennen en die	*X* Veröffentlichung von hes	anderer Redoute	
scheinen anderen i soll oder	zu lassen, oder durch die das Veröffentlichungstelleinalt er- m Recherchenbencht genannten Veröffentlichung belegt werden die aus einem anderen besonderen Grund angegeben ist (wie d)	erfinderischer Tätigkeit t *Y* Veröffentlichung von be-	ser Veröffentlicht Deruhend betrach	ing, die beansprüchte Erfindung ing nicht als neu oder auf let werden
)" Veroftentli	CDUDO, die sich auf eine mündliche, Ottonberge	werden, wenn die Veröff	entlichung mit au	or oder meh
Veröffentlid	nzung, eine Ausstellung oder andere Maßnahmen bezieht chung, die vor dem internationalen. Anmeldedatum, aber nach is	diese Verbindung für ein	en Fachmann na	heliegend jet
GOTT POAL	spruchten Prioritätsdatum veröffentlicht worden ist chlusses der internationalen Recherche	a veroπentlichung, die Mitg	lied derselben P	atentfamilie ist
20	Februar 2001	Absendedatum des inter	nanonalen Hech	erchenberichts
		07/03/2001		
mie una Post	anschrift der Internationalen Recherchenbehörde Europäisches Patentamt, P.B. 5818 Patentlaan 2	Bevollmächtigter Bedien:	steter	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Borst, M		
blatt PCT/ISA/2	10 (Blaff 2) (Julii 1992)	501 3 t , 19		_

INTERNATIONALER RECHERCHENBERICHT

es Patentdokun		Datum der	IVI	litgliød(er) der		Datum der
	angeführtes Patentdokument		Patentfamilie		Veröffentlichung	
1298084	Α	29-11-1972	BE	74352	26 A	28-05-1970
			CA	94628		30-04 - 1974
			СН	50628		30-04-1971
						23-07-1970
						16-03-1973
						20-03-1980
						02-10-1973
						02-07-1970
						26-11-1973
			SU	39685	59 A	29-08-1973
1355324	A	05-06-1974	FR	213502	21 A	15-12-1972
			FR	210056	51 A	24-03-1972
			BE	77016	52 A	01-12-1971
			CA	94468	39 A	02-04-1974
			СН	54004	16 A	15-08-1973
						16-03-1972
						21-04-1980
			NL	711036	51 A	01-02-1972
0704207	Α	03-04-1996	DE	941406	55 U	03-11-1994
			CZ	950223	35 A	13-03-1996
			ΗU			28-05-1997
			JP			19-03-1996
						08-01-1997
			US	570518	39 A	06-01-1998
0727205	Α	21-08-1996	DE	2950254	17 U	30-03-1995
	 0704207	0704207 A	0704207 A 03-04-1996	FR BE CA CH DE IT NL 0704207 A 03-04-1996 DE CZ HU JP SK US	FR 160518 IT 104419 JP 4803188 NL 691952 SE 36203 SU 39688 1355324 A 05-06-1974 FR 213502 FR 210056 BE 77016 CA 94468 CH 54004 DE 213723 IT 104498 NL 711036 0704207 A 03-04-1996 DE 941406 CZ 950223 HU 7523 JP 807337 SK 10629 US 570518	FR 1605150 A IT 1044195 B JP 48031887 B NL 6919520 A SE 362011 B SU 396859 A 1355324 A 05-06-1974 FR 2135021 A FR 2100561 A BE 770162 A CA 944689 A CH 540046 A DE 2137213 A IT 1044956 B NL 7110361 A 0704207 A 03-04-1996 DE 9414065 U CZ 9502235 A HU 75239 A JP 8073378 A SK 106295 A US 5705189 A

Inte ongles Aktenzeichen